Sanofi Reports Strong 2025 Growth, Projects Continued Expansion
Sanofi announced strong sales growth for the fourth quarter and full year 2025, with an increase in business earnings per share. The company anticipates continued profitable growth in 2026.
Paris – Pharmaceutical company Sanofi reported a robust performance for 2025, with sales increasing by 13.3% at constant exchange rates in the fourth quarter. For the full year 2025, sales rose by 9.9% and business earnings per share (EPS) grew by 15.0% at constant exchange rates.
New pharmaceutical launches, including Ayvaait and ALTUVIIIO, saw sales jump by 49.4% to €1.1 billion. Dupixent sales also increased by 32.2% to €4.2 billion. Sales for vaccines declined by 2.5% to €2.0 billion.
Looking ahead to 2026, Sanofi forecasts sales growth in the high single digits, with business EPS expected to grow slightly faster. The company projects profitable growth to continue for at least the next five years. This outlook follows a year where research and development expenses increased by 6.6% to €2.3 billion, and selling, general, and administrative expenses rose by 9.6% to €2.7 billion, supporting new product introductions.
The company also secured ten regulatory approvals across various therapeutic areas and reported several positive Phase 3 clinical trial readouts during the period, bolstering its pipeline and future product offerings.